Neuroscience of aging explained

See also: Aging. The neuroscience of aging is the study of the changes in the nervous system that occur with ageing. Aging is associated with many changes in the central nervous system, such as mild atrophy of the cortex that is considered non-pathological. Aging is also associated with many neurological and neurodegenerative disease such as amyotrophic lateral sclerosis, dementia, mild cognitive impairment, Parkinson's disease, and Creutzfeldt–Jakob disease.[1]

Normal structural and neural changes

Neurogenesis occurs very little in adults, only occurring in the hypothalamus and striatum to a small extent in a process called adult neurogenesis. The volume of the brain actually decrease roughly 5% per decade after forty. It is currently unclear why brain volume decreases with age, however, a few causes may include: cell death, decreased cell volume, and changes in synaptic structure. The changes in brain volume is heterogenous across regions with prefrontal cortex receiving the most significant reduction in volume followed in order by the striatum, the temporal lobe, cerebellar vermis, cerebellar hemispheres, and the hippocampus.[2] However, one review found that the amygdala and ventromedial prefrontal cortex remained relatively free of atrophy, which is consistent with the finding of emotional stability occurring with non-pathological aging.[3] Enlargement of the ventricles, sulci and fissures are also common in non-pathological aging.[4]

Changes may also be associated with neuroplasticity, synaptic functionality and voltage gated calcium channels.[5] Increased magnitude of hyperpolarization, possibly a result of dysfunctional calcium regulation, leads to decreased firing rate of neurons and decreased plasticity. This effect is particularly pronounced in the hippocampus of aged animals, and may be an important contributor to age-associated memory deficits. The hyperpolarization of a neuron can be divided into three stages: the fast, medium and slow hyperpolarization. In aged neurons, the medium and slow hyperpolarization phases involve the prolonged opening of calcium-dependent potassium channels. The prolonging of this phase has been hypothesized to be a result of deregulated calcium and hypoactivity of cholinergic, dopaminergic, serotonergic and glutaminergic pathways.[6]

Normal functional changes

Episodic memory starts to decline gradually from middle age, while semantic memory increases all the way into early old age and declines thereafter.[7] Older adults tend to engage their prefrontal cortex more often during working memory tasks, possibly to compensate with executive functions. Further impairments of cognitive function associated with aging include decrease in processing speed and inability to focus. A model proposed to account for altered activation posits that decreased neural efficiency driven by amyloid plaques and decreased dopamine functionality lead to compensatory activation.[8] Decreased processing of negative stimuli as opposed to positive stimuli appear in aging, become significant enough to detect even with autonomic nervous responses to emotionally charged stimuli.[9] Aging is also associated with decreased plantar reflex and achilles reflex response. Nerve conductance also decreases during normal aging.[10]

DNA damage

Certain genes of the human frontal cortex display reduced transcriptional expression after age 40, and especially after age 70.[11] In particular, genes that have central roles in synaptic plasticity display reduced expression with age. The promoters of genes with reduced expression in the cortex of older individuals have a marked increase in DNA damage, likely oxidative DNA damage.

Pathological changes

See also: Geriatric neurology. Roughly 20% of persons greater than 60 years of age have a neurological disorder, with episodic disorders being the most common followed by extrapyramidal movement disorders, and nerve disorders.[12] Diseases commonly associated with old age include

The misfolding of proteins is a common component of the proposed pathophysiology of many diseases associated with aging, however there is insufficient evidence to prove this. For example, the tau hypothesis to Alzheimer's proposes that tau protein accumulation results in the breakdown neuron cytoskeletons leading to Alzheimer's.[22] Another proposed mechanism for Alzheimer's is related to the accumulation of amyloid beta,.[23] in a similar mechanism to the prion propagation of Creutzfeldt-Jakob disease. Similarly the protein alpha-synuclein is hypothesized to accumulate in Parkinson's and related diseases.[24]

Chemo brain

Treatments with anticancer chemotherapeutic agents often are toxic to the cells of the brain, leading to memory loss and cognitive dysfunction that can persist long after the period of exposure. This condition, termed chemo brain, appears to be due to DNA damages that cause epigenetic changes in the brain that accelerate the brain aging process.[25]

Management

Treatment of an age related neurological disease varies from disease to disease. Modifiable risk factors for dementia include diabetes, hypertension, smoking, hyperhomocysteinemia, hypercholesterolemia, and obesity (which is usually associated with many other risk factors for dementia). Paradoxically, smoking confers protection against Parkinson's disease.[26] Also conferring protective benefits to age related neurological disease in consumption of coffee or caffeine.[27] [28] [29] Consumption of fruits, fish and vegetables confer protection against dementia, as does a Mediterranean diet.[30] Physical exercise significantly lowers the risk of cognitive decline in old age,[31] and is an effective treatment for those with dementia[32] [33] and Parkinson's disease.[34] [35] [36] [37]

Notes and References

  1. Brown. Rebecca C.. Lockwood. Alan H.. Sonawane. Babasaheb R.. Neurodegenerative Diseases: An Overview of Environmental Risk Factors. Environmental Health Perspectives. 8 January 2017. 113. 9. 1250–1256. 10.1289/ehp.7567. 1280411. 0091-6765. 16140637.
  2. Peters. R. Ageing and the brain. Postgraduate Medical Journal. 8 January 2017. 82. 964. 84–88. 10.1136/pgmj.2005.036665. 2596698. 0032-5473. 16461469.
  3. Mather. Mara. The Affective Neuroscience of Aging. Annual Review of Psychology. 5 October 2015. 67. 1. 213–238. 10.1146/annurev-psych-122414-033540. 5780182. 26436717.
  4. LeMay. Marjorie. Radiologic Changes of the Aging Brain and Skull. American Journal of Neuroradiology. 1984. 5. 269–275.
  5. Kelly. K. M.. Nadon. N. L.. Morrison. J. H.. Thibault. O.. Barnes. C. A.. Blalock. E. M.. The neurobiology of aging. Epilepsy Research. 1 January 2006. 68. Suppl 1 . S5–20. 10.1016/j.eplepsyres.2005.07.015. 16386406. 17123597. 0920-1211.
  6. Kumar. Ashok. Foster. Thomas C.. Neurophysiology of Old Neurons and Synapses. Brain Aging: Models, Methods, and Mechanisms. Frontiers in Neuroscience. 1 January 2007. CRC Press/Taylor & Francis. 21204354. 9780849338182.
  7. Peters. R. Ageing and the brain. Postgraduate Medical Journal. 8 January 2017. 82. 964. 84–88. 10.1136/pgmj.2005.036665. 2596698. 0032-5473. 16461469.
  8. Reuter-Lorenz. Patricia A.. Park. Denise C.. Human Neuroscience and the Aging Mind: A New Look at Old Problems. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences. 8 January 2017. 65B. 4. 405–415. 10.1093/geronb/gbq035. 2883872. 1079-5014. 20478901.
  9. Kaszniak. Alfred W.. Menchola. Marisa. Behavioral neuroscience of emotion in aging. Current Topics in Behavioral Neurosciences. 1 January 2012. 10. 51–66. 10.1007/7854_2011_163. 21910076. 978-3-642-23874-1. 1866-3370.
  10. Stanton. Biba R.. The neurology of old age. Clinical Medicine. 1 February 2011. 11. 1. 54–56. 10.7861/clinmedicine.11-1-54. en. 1470-2118. 5873804. 21404786.
  11. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA . Gene regulation and DNA damage in the ageing human brain . Nature . 429 . 6994 . 883–91 . June 2004 . 15190254 . 10.1038/nature02661 . 2004Natur.429..883L . 1867993 .
  12. Callixte. Kuate-Tegueu. Clet. Tchaleu Benjamin. Jacques. Doumbe. Faustin. Yepnjio. François. Dartigues Jean. Maturin. Tabue-Teguo. The pattern of neurological diseases in elderly people in outpatient consultations in Sub-Saharan Africa. BMC Research Notes. 17 April 2015. 8. 159. 10.1186/s13104-015-1116-x. 4405818. 1756-0500. 25880073 . free .
  13. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN . Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study . Brain . 2008 . 10.1093/brain/awn291 . 132 . 156–71 . 19029129 . Pt 1 . 2638696.
  14. Book: Carroll. William M.. International Neurology. 2016. John Wiley & Sons. 9781118777367. 188.
  15. Mendez MF. Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. Archives of Medical Research. November 2012. 43. 8. 677–85. 23178565. 10.1016/j.arcmed.2012.11.009. 3532551.
  16. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM . Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study . Stroke . 33 . 1 . 21–5 . January 2002 . 11779883 . 10.1161/hs0102.101629 . free .
  17. Kiernan. MC. Vucic. S. Cheah. BC. Turner. MR. Eisen. A. Hardiman. O. Burrell. JR. Zoing. MC. Amyotrophic lateral sclerosis.. Lancet. 12 March 2011. 377. 9769. 942–55. 21296405. 10.1016/s0140-6736(10)61156-7. 14354178.
  18. Belay. Ermias D.. Schonberger. Lawrence B.. Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Clinics in Laboratory Medicine. 1 December 2002. 22. 4. 849–862, v-vi. 12489284. 0272-2712. 10.1016/s0272-2712(02)00024-0.
  19. Snowden JS, Neary D, Mann DM . Frontotemporal dementia . Br J Psychiatry . 180 . 2. 140–3 . February 2002 . 11823324 . 10.1192/bjp.180.2.140 . Neary . Mann . free .
  20. Book: Dickson. Dennis. Weller. Roy O.. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. 2011. John Wiley & Sons. 9781444341232. 224. 2. en.
  21. Web site: Corticobasal Degeneration Information Page: National Institute of Neurological Disorders and Stroke (NINDS) . 2009-03-20 . https://web.archive.org/web/20090323180443/http://www.ninds.nih.gov/disorders/corticobasal_degeneration/corticobasal_degeneration.htm . 2009-03-23 . dead .
  22. Goedert. M.. Spillantini. M. G.. Crowther. R. A.. Tau proteins and neurofibrillary degeneration. Brain Pathology (Zurich, Switzerland). 1 July 1991. 1. 4. 279–286. 1669718. 1015-6305. 10.1111/j.1750-3639.1991.tb00671.x. 33331924. free.
  23. Hardy J, Allsop D . Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease . Trends in Pharmacological Sciences . 12 . 10 . 383–88 . 1991 . 1763432 . 10.1016/0165-6147(91)90609-V . October 1991.
  24. Galpern. Wendy R.. Lang. Anthony E.. Interface between tauopathies and synucleinopathies: a tale of two proteins. Annals of Neurology. 1 March 2006. 59. 3. 449–458. 10.1002/ana.20819. 16489609. 19395939. 0364-5134.
  25. Kovalchuk A, Kolb B . Chemo brain: From discerning mechanisms to lifting the brain fog-An aging connection . Cell Cycle . 16 . 14 . 1345–1349 . July 2017 . 28657421 . 5539816 . 10.1080/15384101.2017.1334022 .
  26. Barranco Quintana. JL. Allam. MF. Del Castillo. AS. Navajas. RF. Parkinson's disease and tea: a quantitative review.. Journal of the American College of Nutrition. February 2009. 28. 1. 1–6. 19571153. 10.1080/07315724.2009.10719754. 26605333.
  27. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N . Caffeine intake and dementia: systematic review and meta-analysis . J. Alzheimers Dis. . 20 . S187–204 . 2010 . Suppl 1 . 20182026 . 10.3233/JAD-2010-091387 . free .
  28. Marques S, Batalha VL, Lopes LV, Outeiro TF . Modulating Alzheimer's disease through caffeine: a putative link to epigenetics . J. Alzheimers Dis. . 24 . 2 . 161–71 . 2011 . 21427489 . 10.3233/JAD-2011-110032 .
  29. Arendash GW, Cao C . Caffeine and coffee as therapeutics against Alzheimer's disease . J. Alzheimers Dis. . 20 . S117–26 . 2010 . Suppl 1 . 20182037 . 10.3233/JAD-2010-091249 . free .
  30. Lourida. Ilianna. Soni. Maya. Thompson-Coon. Joanna. Purandare. Nitin. Lang. Iain A.. Ukoumunne. Obioha C.. Llewellyn. David J.. Mediterranean Diet, Cognitive Function, and Dementia. Epidemiology. July 2013. 24. 4. 479–489. 10.1097/EDE.0b013e3182944410. 23680940. 19602773. free.
  31. Andrade. Chittaranjan. Radhakrishnan. Rajiv. The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian Journal of Psychiatry. 1 January 2009. 51. 1. 12–25. 10.4103/0019-5545.44900. 2738400. 0019-5545. 19742190 . free .
  32. Farina N, Rusted J, Tabet N . The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review . Int Psychogeriatr . 26 . 1 . 9–18 . January 2014 . 23962667 . 10.1017/S1041610213001385 . 24936334 .
  33. Rao AK, Chou A, Bursley B, Smulofsky J, Jezequel J . Systematic review of the effects of exercise on activities of daily living in people with Alzheimer's disease . Am J Occup Ther . 68 . 1 . 50–56 . January 2014 . 24367955 . 10.5014/ajot.2014.009035. 5360200 .
  34. Mattson MP . Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy . J Parkinsons Dis . 4 . 1 . 1–13 . 2014 . 24473219 . 10.3233/JPD-130335 . free .
  35. Grazina R, Massano J . Physical exercise and Parkinson's disease: influence on symptoms, disease course and prevention . Rev Neurosci . 24 . 2 . 139–152 . 2013 . 23492553 . 10.1515/revneuro-2012-0087 . 33890283 .
  36. van der Kolk NM, King LA . Effects of exercise on mobility in people with Parkinson's disease . Mov. Disord. . 28 . 11 . 1587–1596 . September 2013 . 24132847 . 10.1002/mds.25658 . 22822120 .
  37. Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Wheatley K, Ives N . Physiotherapy versus placebo or no intervention in Parkinson's disease . Cochrane Database Syst Rev . 9 . CD002817 . September 2013 . 9 . 24018704 . 10.1002/14651858.CD002817.pub4 . 7120224 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Neuroscience of aging".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.